Updated Data from JP28927 Study of Alectinib in ALK plus NSCLC Patients with or without History of ALK Inhibitor Treatment

被引：0
|
作者：
Hotta, Katsuyuki [1 ]
Hida, Toyoaki [2 ]
Nakagawa, Kazuhiko [3 ]
Seto, Takashi [4 ]
Satouchi, Miyako [5 ]
Nishio, Makoto [6 ]
Murakami, Haruyasu [7 ]
Ohe, Yuichiro [8 ]
Takeda, Koji [9 ]
Yoshimoto, Takuya [10 ]
Tanaka, Tomohiro [10 ]
Tamura, Tomohide [11 ]
机构：
[1] Okayama Univ Hosp, Okayama, Japan
[2] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
[3] Kinki Univ, Fac Med, Osaka, Japan
[4] Kyushu Natl Canc Ctr, Fukuoka, Japan
[5] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[6] Jfcr, Canc Inst Hosp, Tokyo, Japan
[7] Shizuoka Canc Ctr, Shizuoka, Japan
[8] Natl Canc Ctr, Tokyo, Japan
[9] Osaka City Gen Hosp, Osaka, Japan
[10] Chugai Pharmaceut Co Ltd, Tokyo, Japan
[11] St LukeS Int Hosp, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Alectinib; ALK plus NSCLC; ALK Inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-020
引用
收藏
页码：S648 / S648
页数：1
相关论文
共 50 条
  • [11] Alectinib vs crizotinib in treatment-naive ALK plus NSCLC: CNS efficacy results from the ALEX study
    Gadgeel, S.
    Peters, S.
    Mok, T. S. K.
    Shaw, A. T.
    Kim, D-W.
    Ou, S-H. I.
    Perol, M.
    Dziadziuszko, R.
    Ahn, J. S.
    Rosell, R.
    Zeaiter, A.
    Mitry, E.
    Nueesch, E.
    Balas, B.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [12] NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IBIII ALK plus NSCLC
    Lee, J. M.
    Toloza, E. M.
    Pass, H. I.
    Johnson, B. E.
    Heymach, J. V.
    Sholl, L.
    Saqi, A.
    Travis, W. D.
    Wistuba, I.
    Lin, J.
    Kris, M. G.
    Spira, A. I.
    Shu, C. A.
    Saltos, A. N.
    Ding, B.
    Schulze, K.
    Zhu, Q.
    Ngiam, C.
    Bara, I.
    Chaft, J. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S297 - S298
  • [13] ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK plus ) NSCLC Patients in the US Community Oncology Setting
    Waterhouse, D.
    Espirito, J.
    Chioda, M.
    Baidoo, B.
    Mardekian, J.
    Robert, N.
    Masters, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S560
  • [14] The efficacy and safety of alectinib in the treatment of ALK plus NSCLC: a systematic review and meta-analysis
    Fan, Junsheng
    Xia, Zengfei
    Zhang, Xiaoli
    Chen, Yuqing
    Qian, Ruolan
    Liu, Sihan
    You, Danming
    Zhang, Jian
    Luo, Peng
    ONCOTARGETS AND THERAPY, 2018, 11 : 1105 - 1115
  • [15] Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK plus NSCLC.
    Camidge, D. Ross
    Peters, Solange
    Mok, Tony
    Gadgeel, Shirish M.
    Cheema, Parneet K.
    Pavlakis, Nick
    De Marinis, Filippo
    Stroyakovskiy, Daniil L.
    Cho, Byoung Chul
    Zhang, Li
    Moro-Sibilot, Denis
    Zeaiter, Ali Hassan
    Mitry, Emmanuel
    Balas, Bogdana
    Mueller, Barbara
    Shaw, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [16] Role of QoL in Treatment Decisions for Patients with ALK plus NSCLC
    Law, H.
    King, J. C.
    Lin, H. M.
    Curran, E.
    Wiens, J.
    Cruz, L.
    Blender, J.
    Venanzi, E. S.
    Schenk, E.
    Lin, J. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S113 - S114
  • [17] ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA
    Gettinger, S.
    Bazhenova, L.
    Salgia, R.
    Langer, C.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [18] Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK plus NSCLC
    Leal, Ticiana
    Wakelee, Heather
    Infante, Jeffrey
    Blumenschein, George
    Reckamp, Karen
    Carter, Corey
    Waqar, Saiama
    Gockerman, Jon
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S209 - S210
  • [19] Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK plus advanced NSCLC (aNSCLC).
    Kim, Dong-Wan
    Gadgeel, Shirish M.
    Gettinger, Scott N.
    Riely, Gregory J.
    Oxnard, Geoffrey R.
    Mekhail, Tarek
    Schmid, Peter
    Dowlati, Afshin
    Heist, Rebecca Suk
    Wozniak, Antoinette J.
    Hernandez, Genevive
    Sarkar, Indrani
    Mitry, Emmanuel
    Foster, Paul
    O'Hear, Carol
    Spahn, Jessica
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [20] A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK plus NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.
    Ohe, Yuichiro
    Nishio, Makoto
    Kiura, Katsuyuki
    Seto, Takashi
    Nakagawa, Kazuhiko
    Maemondo, Makoto
    Inoue, Akira
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Harada, Masao
    Nogami, Naoyuki
    Murakami, Haruyasu
    Takeuchi, Kengo
    Shimada, Tadashi
    Kuriki, Hiroshi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345